LBRX (LB Pharmaceuticals) Current Accrued Expense: $1.71 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $34.80
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals Current Accrued Expense?

LB Pharmaceuticals LBRX +0.23% 12 Current Accrued Expense is $1.71 Mil as of Mar. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

LB Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2026 was $1.71 Mil.

LB Pharmaceuticals's quarterly Current Accrued Expense increased from Sep. 2025 ($1.33 Mil) to Dec. 2025 ($2.39 Mil) but then declined from Dec. 2025 ($2.39 Mil) to Mar. 2026 ($1.71 Mil).

LB Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($0.42 Mil) to Dec. 2024 ($3.06 Mil) but then declined from Dec. 2024 ($3.06 Mil) to Dec. 2025 ($2.39 Mil).

LB Pharmaceuticals Current Accrued Expense Related Terms

LB Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for LB Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LB Pharmaceuticals Current Accrued Expense Chart

LB Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
0.09 0.42 3.06 2.39

LB Pharmaceuticals Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.56 1.33 2.39 1.71
LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.71 Mil mean?
LB Pharmaceuticals (LBRX) has a Current Accrued Expense of $1.71 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on LB Pharmaceuticals and its competitors.
Is LB Pharmaceuticals' Current Accrued Expense too high?
LB Pharmaceuticals' current Current Accrued Expense is $1.71 Mil. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' Current Accrued Expense compare to MRVI and LXRX?
LB Pharmaceuticals' Current Accrued Expense of $1.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on LB Pharmaceuticals and its competitors. LB Pharmaceuticals's current Current Accrued Expense is $1.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current Current Accrued Expense of $1.71 Mil. The current Current Accrued Expense is $1.71 Mil. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current Current Accrued Expense is $1.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.80
Price